A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity.
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
After watching this activity, participants should be better able to:
- Describe the immunopathogenesis of cold agglutinin disease (CAD) and implications for effective patient management
- Appraise current and emerging treatment options for patients with CAD using the latest data
- Evaluate strategies to individualize the treatment and management of patients with CAD
In this activity, three experts discuss the pathogenesis of cold agglutinin disease (CAD) and consider the current diagnostic pathway and differential diagnoses, as well as the role of complement inhibitors as an emerging treatment option for patients with primary CAD. The discussion is guided by pre-canvassed questions provided by the haematological clinical community.
This activity is jointly provided by USF Health and touchIME. read more
This activity has been designed to meet the educational needs of haematologists and haematologist-oncologists involved in the management of cold agglutinin disease.
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Prof. Morie Gertz discloses: Advisory board/panel fees from AbbVie, Aptitude, Ashfield, Celgene, Ionis/Akcea, Janssen, Johnson & Johnson, Prothena, Sanofi and Sorrento. Grants/research support from: Ashfield and Juno.
Prof. Bernd Jilma discloses: Advisory board/panel and speaker’s bureau fees from Sanofi.
Dr Shirley D’Sa discloses: Advisory board/panel fees from BeiGene, Janssen and Sanofi. Consultancy fees from BeiGene and Sanofi. Grants/research support and speaker’s bureau fees from BeiGene.
Caitlin Papa, MSN, APRN-C has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Directors
Kathy Day and Sadaf Kazi have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact firstname.lastname@example.org.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 05 October 2022. Date credits expire: 05 October 2023.
If you have any questions regarding credit please contact email@example.com.
To obtain the CME credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Foreword – touchREVIEWS in RMD Vol 1 Issue 2 – 2022
Foreword – touchREVIEWS in RMD Vol 1 Issue 1 – 2022
Olivier Bruyère, WCO IOF-ESCEO 2022: the Impact of Sarcopenia on Quality of Life
Unravelling endotypes for treatment selection in severe type 2 asthmaThis activity is CE/CME accredited
Nina Muirhead: Updated NICE ME/CFS Guidance
Eosinophilic inflammatory diseases of the respiratory system: New therapeutic optionsThis activity is CE/CME accredited
Register to touchIMMUNOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!